Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:3 Issue:6 Number:6 ISSN#:2563-5476
Author Verified
ACE Report #6038
Ace Report Cover Metabolic Disorders

Denosumab is superior to alendronate for improving cortical bone porosity post-menopause

How to Cite

OrthoEvidence. Denosumab is superior to alendronate for improving cortical bone porosity post-menopause. ACE Report. 2014;3(6):6. Available from: https://myorthoevidene.com/AceReport/Report/6038

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Differing effects of denosumab and alendronate on cortical and trabecular bone

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

Contributing Authors: RM Zebaze C Libanati M Austin A Ghasem-Zadeh DA Hanley JR Zanchetta T Thomas S Boutroy CE Bogado JP Bilezikian E Seeman

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Two hundred and forty-seven post-menopausal women (146 with data at final follow-up) received a subcutaneous injection every 6 months and a pill weekly. These treatments were randomized as follows: Group one received denosumab injections and a placebo pill, Group two received alendronate and a placebo injection and Group three received a placebo injection and pill. The purpose of this trial wa...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.